Amylyx Pharmaceuticals (AMLX) Expected to Announce Earnings on Thursday

Amylyx Pharmaceuticals (NASDAQ:AMLX) is anticipated to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.3609) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). On average, analysts expect Amylyx Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Amylyx Pharmaceuticals Price Performance

Shares of NASDAQ:AMLX traded up $0.71 during midday trading on Tuesday, hitting $20.88. The company had a trading volume of 105,936 shares, compared to its average volume of 1,371,567. Amylyx Pharmaceuticals has a twelve month low of $7.48 and a twelve month high of $20.95. The stock has a market cap of $2.32 billion, a price-to-earnings ratio of -13.92 and a beta of -0.21. The business’s 50-day simple moving average is $16.68 and its 200-day simple moving average is $15.52.

Insiders Place Their Bets

In related news, insider Gina Mazzariello sold 15,000 shares of Amylyx Pharmaceuticals stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total value of $274,800.00. Following the completion of the transaction, the insider directly owned 194,090 shares in the company, valued at approximately $3,555,728.80. This trade represents a 7.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 10.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Meeder Asset Management Inc. acquired a new position in shares of Amylyx Pharmaceuticals during the 4th quarter worth $25,000. California State Teachers Retirement System acquired a new position in shares of Amylyx Pharmaceuticals during the 2nd quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd boosted its position in Amylyx Pharmaceuticals by 1,116.9% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,454 shares of the company’s stock worth $54,000 after acquiring an additional 4,088 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in Amylyx Pharmaceuticals by 433.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock valued at $47,000 after acquiring an additional 5,904 shares during the last quarter. Finally, Legal & General Group Plc purchased a new position in Amylyx Pharmaceuticals during the second quarter worth about $47,000. 95.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have issued reports on AMLX. Guggenheim upped their target price on Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, June 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Friday, May 8th. HC Wainwright reissued a “buy” rating and set a $34.00 price target on shares of Amylyx Pharmaceuticals in a research report on Monday, June 8th. Wall Street Zen lowered shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Mizuho raised their price objective on shares of Amylyx Pharmaceuticals from $21.00 to $24.00 and gave the stock an “outperform” rating in a research report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Amylyx Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $25.38.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.